Evaxion Biotech AS (EVAX) Quote

EVAX........................................https://stockcharts.com/h-sc/ui?s=EVAX&p=W&b=5&g=0&id=p86431144783

$4.91 + 100% this round 

EVAX (4-Mil. Flt., 3%): $2.40, 31%; (Open-M) news, $14 target by Wainwright; infect. diseases, cancer, vaccines (Denmark).

yeah, a 1M float will do this. $11pm one day and then down she goes.

Currently $11 😙

EVAX.........................https://stockcharts.com/h-sc/ui?s=EVAX&p=W&b=5&g=0&id=p86431144783

At $4s now $14s not long ago 

$6.02 having a convulsion

evax.....................https://stockcharts.com/h-sc/ui?s=evax&p=W&b=5&g=0&id=p86431144783

PROXY out https://www.otcmarkets.com/filing/html?id=18071025&guid=lKY-kHdxdv3Th3h

Was once a high-flying ticket.

EVAX....................https://stockcharts.com/h-sc/ui?s=EVAX&p=W&b=5&g=0&id=p86431144783

$2.04 + 120% looks good $14 looked best lol

$1.90

Hot off the presses $1.64 + 83%

EVAX.....................https://stockcharts.com/h-sc/ui?s=EVAX&p=W&b=5&g=0&id=p86431144783

EVAX under $3

EVAX under $3

EVAX under $3

EVAX under $5

EVAX under $5

EVAX new 52 week low

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

Halted. Offering exercise @ $4???? no way, that'll get reoffered for lower imo.

https://www.globenewswire.com/news-release/2024/02/01/2822093/0/en/Evaxion-Biotech-Announces-Pricing-of-15-Million-Public-Offering.html

#EVAX 🔥 low float crazy stock! Can run big tomorrow! $evax

Thanks! 14.77 is INSANITY! Hey, look what is going on with AFIB. No news since November. I used to trade that one in the past and banked several times

nice trading, you got ,more than me

this POS hit 14.77 ah

got out at $12 and we make a nice living on buying and selling these POS Companies! :)))))

LOL

$EVAX Jan. 24, 2024, 07:32 AM
InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Evaxion Biotech (NASDAQ:EVAX) stock is on the rise Wednesday after the company revealed a stake held by Merck (NYSE:MRK).

A filing with the Securities and Exchange Commission (SEC) notes that Merck now holds an 11.4% stake in Evaxion Biotech. That comes from the 2,297,884 shares of EVAX and warrants to acquire another 2,297,704 shares that the company owns.

The stake that Merck holds is based on the 40,204,700 shares outstanding as of Jan. 11, 2024. That comes from 37,906,996 shares of MRK stock outstanding and 2,297,704 shares issuable upon the exercise of warrants.

It's amazing what a couple of keywords can do! Excellent IR work. I got out at $12 and we make a nice living on buying and selling these POS Companies! :)))))

$13'S ON THAT NEWS, POST RS PLAYS CAN BE WILD

I BOUGHT AS LOW AS 7.77 BUY DIDNT HOLD


WHERE DID YOU SELL?

Message in reply to:
LOL. Looks fake but I'll take it, man! :)

$11.93 and halted again

OF COURSE 9.72 HALTED UP

OPEN $10+

Hey! its all about making $$$$ :)

9.50 WAS MY HIGHEST SELL

NOW 8.50

I SEE IT NOW... 1-10 RS

WHAT HAPPENED ON THE 22ND FOR EVAX TO DROP TO 3.36? -45%


Jan 23 2024 4.99 1.33 36.29% 5.55 5.57 4.15 1,225,974
Jan 22 2024 3.6612 -3.04 -45.36% 6.94 6.94 3.36 212,44

WHAT HAPPENED ON THE 22ND FOR NVAX TO DROP TO 3.36? -45%


Jan 23 2024 4.99 1.33 36.29% 5.55 5.57 4.15 1,225,974
Jan 22 2024 3.6612 -3.04 -45.36% 6.94 6.94 3.36 212,44

;LOOKS LIKE $10+ COMING SOON

Yeah, but well-written fluff. Took a position last night,not gonna hold it long

EVAX 8.88 you mean fluff?

LOL. Looks fake but I'll take it, man! :)

LOL. Looks fake but I'll take it, man! :)

EVAX 7.77 Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
https://www.globenewswire.com/news-release/2024/01/24/2815320/0/en/Evaxion-to-Develop-Tailored-Novel-Cancer-Vaccines-Based-upon-a-New-Untapped-Source-of-AI-Discovered-Targets.html

https://finviz.com/quote.ashx?t=EVAX&p=d#google_vignette

LOL

Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets

NEWS
Evaxion Announces Completion of ADS Ratio Change
COPENHAGEN, Denmark, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that the Company’s previously disclosed change to its ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS Ratio”), has been made effective. The ratio has changed from one (1) ADS representing one (1) ordinary share to a new ADS Ratio of one (1) ADS representing ten (10) ordinary shares (the “ADS Ratio Change”). The ADS Ratio Change became effective on January 22, 2024 (the “Effective Date”).

For the Company's ADS holders, the change in the ADS Ratio has the same effect as a one-for-ten reverse ADS split and is intended to further support the liquidity in the Company’s ADSs and to enable the Company to regain compliance with the Nasdaq minimum bid price requirement. The exchange of one (1) new ADS for every ten (10) then-held (existing) ADSs occurred automatically on the Effective Date, with the then-held ADSs being cancelled and new ADSs being issued by The Bank of New York Mellon, the depositary bank (the “Depositary”). Registered holders of the Company’s ADSs held in certificated form were required on a mandatory basis to surrender their certificated ADSs to the Depositary for cancellation and received one (1) new ADS in exchange for every ten (10) existing ADSs then-held. Holders of uncertificated ADSs in the Direct Registration System (DRS) and The Depository Trust Company (DTC) had their ADSs cancelled and automatically exchanged, receiving one (1) new ADS for every ten (10) existing ADS then-held. The Company’s ADSs continue to be traded on The Nasdaq Capital Market under the ticker symbol “EVAX”.

The ADS Ratio Change affects all shareholders uniformly and will not alter any shareholder’s percentage interest in the Company’s equity, except to the extent that the ratio change would have resulted in a shareholder owning fractional ADSs. No fractional new ADSs were issued in connection with the change in the ADS Ratio. Instead, fractional entitlements to new ADSs will be aggregated and sold by the Depositary, and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes and expenses) will be distributed to the applicable ADS holders by the Depositary.

As a result of the ADS Ratio Change, the ADS trading price is expected to increase proportionally, although the Company can give no assurance that the ADS trading price after the ADS Ratio Change will be proportionally equal to or greater than the previous ADS trading price prior to the change or that the Ratio Change will have any effect on the liquidity in the Company’s ADSs.

Some would say unnecessary move AH

Of course they just did a RS too

INDESCRIBABLE DUMPING

EVAX: planned one for 10 reverse split for Jan. 22,2024:

https://hedgefollow.com/upcoming-stock-splits.php

Today's range $0.57 - $0.77

Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept

Proof of Concept – Evaxion’s AI-Immunology™ platform demonstrates success in designing precision cancer vaccines in hematological cancers by targeting a novel class of antigens
Broad Applicability – The vaccine concept holds tremendous potential, offering broad applicability and promising benefits for patients with hematological malignancies

COPENHAGEN, Denmark, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, proudly announces the presentation of its novel precision vaccine concept at the 65th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, California, from December 9-12, 2023.

https://ih.advfn.com/stock-market/NASDAQ/evaxion-biotech-as-EVAX/stock-news/92667300/form-6-k-report-of-foreign-issuer-rules-13a-16